A Decade of Progress in Familial Hypercholesterolemia Awareness, Treatment
September 23rd 2024On day 1 of the Family Heart Global Summit, speakers highlighted the critical need for awareness, early diagnosis, and innovative treatment options for familial hypercholesterolemia, sharing significant strides made in the field over the past decade.
Read More
Medicare High-Value Drug List Model Could Lower Out-of-Pocket Costs for 4 in 10 Beneficiaries
September 23rd 2024The proposed Medicare High-Value Drug List Model, also known as the Medicare $2 Drug List, could have modestly reduced out-of-pocket costs for 38% of beneficiaries if implemented in 2021.
Read More
CMMI's Latest Payment Models Address Health Disparities, but Challenges Remain
September 22nd 2024"As CMMI continues to test new equity adjustments, it is important that changes be grounded in scientific principles with extensive testing and validation to ensure the tightest linkage to social needs and health outcomes for underserved communities across the entire US," authors wrote.
Read More
New Research Unearths Evidence of Global Metabolic Disruption in Patients With SMA
September 21st 2024A recent analysis investigated the state of metabolic disruption experienced by patients with spinal muscular atrophy (SMA), adding to the literature on nutritional and metabolic complications linked to SMA.
Read More
FDA Approves Isatuximab With VRd as First-Line Option for Transplant-Ineligible Multiple Myeloma
September 20th 2024Isatuximab (Sarclisa) with bortezomib, lenalidomide, and dexamethasone (VRd) is now an approved option for adults who cannot receive an autologous stem cell transplant to treat their newly diagnosed multiple myeloma.
Read More
FTC Takes Legal Action Against 3 Largest PBMs Over Insulin Costs
September 20th 2024The Federal Trade Commission (FTC) has filed a legal complaint accusing the 3 largest pharmacy benefit managers (PBMs) in the US—Caremark, Express Scripts, and Optum Rx—of inflating insulin costs for patients, prompting renewed calls for PBM reform.
Read More
Multidisciplinary Prehabilitation to Boost Outcomes in AML, MDS for Stem Cell Transplant
September 20th 2024A new study aims to investigate the feasibility and impact of multidisciplinary prehabilitation in adults with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) offered an allogenic hematopoietic stem cell transplantation.
Read More
Varied Types, Levels of Support Needed for Patients With Multiple Myeloma
September 20th 2024Information on the disease and treatments, assistance with insurance, and transportation are among the types of support needed by patients with multiple myeloma to improve outcomes and overall burden.
Read More
Comorbidities Require Special Treatment Consideration for PAH
September 20th 2024In addition to being diagnosed more frequently in older patients, pulmonary arterial hypertension (PAH) is more frequently diagnosed in patients with cardio-pulmonary comorbidities, which poses challenges to the optimal treatment of PAH, explained the researchers.
Read More
FDA Approves Amivantamab for EGFR-Positive NSCLC With Exon 19 Deletion, Exon 21 L858R Substitution
September 20th 2024The FDA approval of amivantamab-vmjw (Rybrevant) in combination with chemotherapy is the first targeted treatment to cut disease progression risk for EGFR-positive non–small cell lung cancer (NSCLC).
Read More